These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32536573)

  • 21. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
    Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
    Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
    Rucinska M; Kieszkowska-Grudny A; Nawrocki S
    Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
    Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
    Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.
    Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y
    Eur J Cancer; 2016 Sep; 65():43-51. PubMed ID: 27459586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
    Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy.
    Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Maucieri A; Gerardi MA; Vischioni B; Cambria R; Garibaldi C; Cattani F; Vavassori A; Matei DV; Musi G; De Cobelli O; Orecchia R
    BJU Int; 2014 Dec; 114(6b):E3-E10. PubMed ID: 24712723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter
    Fink CA; Ristau J; Buchele C; Klüter S; Liermann J; Hoegen-Saßmannshausen P; Sandrini E; Lentz-Hommertgen A; Baumann L; Andratschke N; Baumgartl M; Li M; Reiner M; Corradini S; Hörner-Rieber J; Bonekamp D; Schlemmer HP; Belka C; Guckenberger M; Debus J; Koerber SA
    Clin Transl Radiat Oncol; 2024 May; 46():100771. PubMed ID: 38586081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer.
    Poon DMC; Yang B; Geng H; Wong OL; Chiu ST; Cheung KY; Yu SK; Chiu G; Yuan J
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):841-850. PubMed ID: 35199189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
    King CR; Collins S; Fuller D; Wang PC; Kupelian P; Steinberg M; Katz A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):939-45. PubMed ID: 24119836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
    Mazzola R; Figlia V; Rigo M; Cuccia F; Ricchetti F; Giaj-Levra N; Nicosia L; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2379-2397. PubMed ID: 32372146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
    Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F
    Radiol Med; 2021 Jul; 126(7):989-997. PubMed ID: 33835309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients.
    van Stam MA; Aaronson NK; Pos FJ; Bosch JL; Kieffer JM; Tillier CN; van der Poel HG
    Eur Urol; 2016 Nov; 70(5):751-757. PubMed ID: 27016464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer.
    Mallick I; Arunsingh M; Chakraborty S; Arun B; Prasath S; Roy P; Dabkara D; Achari R; Chatterjee S; Gupta S
    Clin Oncol (R Coll Radiol); 2020 Feb; 32(2):e39-e45. PubMed ID: 31551125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer.
    Bohoudi O; Bruynzeel AME; Tetar S; Slotman BJ; Palacios MA; Lagerwaard FJ
    Radiother Oncol; 2021 Apr; 157():197-202. PubMed ID: 33545251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.
    Yap T; Ahmed HU; Hindley RG; Guillaumier S; McCartan N; Dickinson L; Emberton M; Minhas S
    Eur Urol; 2016 May; 69(5):844-51. PubMed ID: 26525837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
    Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
    Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.